Paramita Therapeutics, Inc. Awarded Competitive Grant From the National Science Foundation
Jul 22, 2021
Paramita Therapeutics, Inc. (Paramita) has been awarded a National Science Foundation Small Business Innovation Research grant for $255,990 to conduct research and development work on a novel dual-function therapeutic/vaccine product, designated as TheraVax™. TheraVax not only can block entry of SARS-CoV-2 but also can activate the immune system to produce effector T cells and neutralizing antibodies to eliminate SARS-CoV-2. This unique dual-function therapeutic/vaccine could work at an early stage of infection to prevent hospitalization and in mild or severe disease to block viral spread while activating appropriate immune responses.
"NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering," said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. "With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs."
"The multivalent chemical conjugation platform that we are developing for COVID-19 will work with other viruses and even cancer cells. Therefore, our platform will have revolutionary impact on society as a whole, not only impacting on the current pandemic but also thwarting future pandemics while providing novel therapies for cancer," said Dr. Sang Van, CEO, Paramita Therapeutics, Inc.
Once a small business is awarded a Phase I SBIR/STTR grant, it becomes eligible to apply for a Phase II (up to $1 million). Small businesses with Phase II funding are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
About Paramita Therapeutics, Inc.: Paramita is an early-stage specialty biotech company focused on developing new therapeutics for cancer and infectious diseases. Paramita can quickly move these new therapeutics to the clinic with our innovative, patented, simple multi-functional chemical platform developed by Dr. Sang Van. We intend to leverage this technology to produce novel multivalent drug conjugates based on known/approved molecules with established safety and toxicology profiles. This strategy allows us to bypass or streamline the extremely expensive and time-consuming process. Paramita is managed by CEO Sang Van, PhD; CSO Jack D. Bui, PhD & MD; and BD Director Sue Zhong, PhD & MBA. www.paramita-therapeutics.com
About the National Science Foundation's Small Business Programs: America's Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development (R&D), helping de-risk technology for commercial success. America's Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.5 billion that supports fundamental research and education across all fields of science and engineering.
Press Release Service by Newswire.com
Original Source: Paramita Therapeutics, Inc. Awarded Competitive Grant From the National Science Foundation
More News
Weak Links Start to Show in A.I. Borrowing
Debt trouble at CoreWeave, Oracle and SoftBank raises questions about whether there is broader trouble with the data center build-out.
Call for more food funding due to high living cost
Deputy Louise Doublet does not think the cost of living was considered in the ending of a trial.
Charity reflects on changing needs over 25 years
Help a Guernsey Child says it has provided in excess of £1.2m worth of essential support.
Nightclubs are disappearing - and it's affecting young people
One young person said with no nightlife in their town they cannot "let loose and mess around".
Netflix Hurries to Rewrite Its Narrative With Layoffs and a Sudden Firing
Despite strong revenues and profits, the streaming service cut 1,000 jobs and jettisoned its chief content officer. Drops in the stock price and viewer engagement are to blame.
Why Bad News in the Bond Market May Be Good News for Investors
In the contrarian logic of investing, rising interest rates have made bonds much more attractive, our columnist says.
U.S. Budget Deficit Nears $2 Trillion, a Reality Check for Trump’s Cost Cutting
Higher interest rates are inflating borrowing costs as the Trump administration spends on the Iran war and tariff refunds.
Indonesian Stocks Plunge as MSCI Threatens to Drop Market from Indexes
The potential downgrade by MSCI, an influential index provider, adds to a deepening crisis of investor confidence in the economic policies of President Prabowo Subianto.
Warsh Vows to Tame Inflation as A.I. Delivers ‘Shock’ to Economy
The Federal Reserve chairman stuck to his pledge to avoid providing guidance about the path forward for interest rates, but did nothing to convey an urgency to raise them later this month.
A new railway corridor: How Nanning links Chinese and ASEAN markets
A new railway corridor: How Nanning links Chinese and ASEAN markets
Watch: Did Tesla really just unveil a flying car?
Tesla CEO Elon Musk showcased the vehicle at a facility owned by his SpaceX company, which helped develop the model.
China and Europe are building new connections in aerospace
China and Europe are building new connections in aerospace – from skies to stars. On the one hand, their deep industrial partnership is scaling global civil aviation to new heights. On the other hand, scientific collaboration is opening new possibilities for space exploration and deepening our understanding of the Sun-Earth system.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.